Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2011 June;36(2) > Minerva Endocrinologica 2011 June;36(2):117-21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

ORIGINAL ARTICLES   

Minerva Endocrinologica 2011 June;36(2):117-21

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Efficacy of low and high fixed dose radioactive iodine therapy in patients with toxic nodular goiter

Sonmez B. 1, Erem C. 2, Dogan I. 1, Ersoz H. O. 2, Sonmez M. 3

1 Department of Nuclear Medicine, Karadeniz Technical University, School of Medicine, Trabzon, Turkey; 2 Department of Endocrinologyand Metabolism, Karadeniz Technical University, School of Medicine, Trabzon, Turkey; 3 Department of Hematology, Karadeniz Technical University, School of Medicine, Trabzon, Turkey;


PDF


AIM: The efficacy of low and high fixed dose radioactive iodine (RAI) therapy in patients with toxic nodular goiter was investigated.
METHODS: Ninety-three patients (25 males, 68 females) were included into the study (32 patients with toxic adenoma, 61 patients with toxic multinodular goiter). Patients were treated with a fixed dose of 370 MBq (10 mCi) or 740 MBq (20 mCi) RAI. The average follow-up period was 17±10 months.
RESULTS: The overall cure rate (eutyhroidism and hypothyroidism) was 81% in patients treated with 740 MBq RAI and 51% in patients treated with 370 MBq RAI (p<0.05). RAI therapy with a dose of 370 MBq and 740 MBq provided the cure in 73% and 91% of the patients with toxic adenoma and 42% and 76% of the patients with toxic multinodular goiter, respectively. No significant difference for gender was observed. Hypothyroidism developed in 4 and 15 patients with a dose of 370 MBq and 740 MBq RAI, respectively.
CONCLUSION: A dose of 740 MBq RAI was found to be more effective for the treatment of toxic nodular goiter as compared to a dose of 370 MBq RAI.

top of page